1. Abdulkadyrov K.M, Turkina A.G, Khoroshko N.D et al. Guidelines for the diagnosis and treatment of chronic myeloid leukemia, 2013. (in Russian)
2. Vinogradova O.YU, Turkina A.G, Vorontsov A.V et al. The use of dasatinib in patients with chronic phase chronic myeloid leukemia with resistance or intolerance to treatment with imatinib. Therapeutic Archives, 2009, № 7, pp. 41-46. (in Russian)
3. Zeifman A.A, E.Y Chelisheva, A.G Turkina, G.G Chilov. Role of tyrosine kinase inhibitor selectivity in the development of side-effects in the treatment of chronic myeloid leukemia. Clinical oncohematology. 2014; Volume 7, N 1, pp. 16-27. (in Russian)
4. Zeifman A.A, Chelisheva E.Y., Turkina A.G., Chilov G.G. Role of tyrosine kinase inhibitor selectivity in the development of side-effects in the treatment of chronic myeloid leukemia // Clin. Оncohematol. 2014. 7. (1). 16–27
5. Anastassiadis T., Deacon S.W., Devarajan K. et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity // Biotechnol. 2011. 29. (11). 1039–1045.
6. Bergeron A., Rea D., Levy V. et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series // Am. J. Respir. Crit. Care Med. 2007. 176. 814–818.
7. Common Terminology Criteria for Adverse Events/Version 3.0. Cancer Therapy Evaluation Program. 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
8. Cortes J., Rousselot P., Kim D.W. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis // Blood. 2007. 109. 3207–3213.
9. Cortes J.E., Hohchaus A., Kim D.W. et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response // Blood. 2013. 122. (21). http://www.bloodjournal.org/content/122/21/653?sso-checked=true
10. De Lavallade H., Punnialingam S., Milujkovic D. et al. Pleural effusion in patients with chronic myeloid leukemia treated with dasatinib may have an immune-mediated pathogenesis // Br. J. Haematol. 2008. 141. 745–747.
11. Guilhot F., Apperley J., Kim D.W. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase // Blood. 2007. 109. 4143–4150.
12. Hochhaus A., Baccarani M., Deiniger M. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib // Leukemia. 2008. 22. 1200–1206.
13. Kantarjian H., Pasquini R., Hamerschlak N. et al. Dasatinib or high-dose imatinib patients with chronic-phase chronic myeloid leukemia after failure of first-line imatinib: randomized phase 2 trial // Blood. 2007. 109. (12). 5143–5150.
14. Kim D.H., Popradi G., Sriharsha L. et al. Risk factors and management of patients with pulmonary abnormalities and Philadelphia chromosome positive leukemia after treatment with dasatinib: results from 2 institutions // Clin. Leukemia. 2008. 2. 55–63.
15. Larson R.A., Hohchaus A., Saglio G. et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update // ASCO Annu. Meet. 2013. abstract 7052. http://meetinglibrary.asco.org/content/111951-132
16. Latagliata R., Breccia M., Fava C. et al. Incidence, risk factors and management of pleural effusion during treatment in unselected elderly patients with chronic myelogenous leukemia // Hematol Oncol. 2013. 31. 103–109.
17. Mustjoki S., Ekblom M., Arstila T.P. et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy // Leukemia. 2009. 23. 1398–1405.
18. O’Hare T., Walters D.K., Stoffregen E.P. et al. In vitro activity of Bcr-Abl ingibitors AMN 107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutans // Cancer Res. 2005. 65. 4500–4505.
19. Paidas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? // Oncology/Hematology. 2014. 89. 242–247.
20. Porkka K., Khoury J., Paquette R.L. et al. Dasatinib 100 mg once daily minimizes the occurence of pleural ffusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion // Cancer. 2010. 116. 377–386.
21. Porkka K., Baccarani M., Cortes J.E. et al. Pleural effusion in patients chronic phase chronic myeloid leukemia (CML-CP) who received first-line dasatinib in the DASISION trial: characteristics, management, and outcomes // EHA Congr. 2011. poster presentation 0692.
22. Quintas-Cardama A., Kantarjian H., O ’Brien S. et al. Pleural effusion in chronic phase chronic myelogeneus leukemia treated with dasatinib after imatinib failure // J. Clin. Oncol. 2007. 25. 3908–3914.
23. Shah N.P., Kim D.W., Kantarjian H. et al. Dasatinib dose optimization in chronic phase chronic myeloid leukemia (CML-CP): two years data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose // Blood (ASH Annu. Meet. Abstr.). 2008. 112. Abstr. 3225.
24. Shah N.P., Kantarjian H., Kim D.W. et al. Intermittent target inhibition with dasatinib100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia // J. Clin. Oncol. 2008. 26. 3204–3212.
25. Shah N.P., Guilhot F., Cortes J.E. et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study // Blood. 2014. 23. 2317–2324.
26. Sprycel (dasatinib) [prescribing information] Prinseton, NJ: Bristol-Myers Squibb Company; 2013.
About Authors (Correspondence):
Gusarova G.A. – candidate of medical sciences, senior researcher of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: galina1966@bk.ru
Turkina A.G. – doctor of medical sciences, professor, head of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: turkianna@yandex.ru
Vorontsova A.V. – candidate of medical sciences, haematologist, e-mail: voroncova9@mail.ru
Goryacheva S.R. – candidate of medical sciences, doctor-hematologist of the scientific advisory department for chemotherapy day hospital, e-mail: svgor@blood.ru
Kuznetsov S.V. – hospital day care haematologist, e-mail: yozhik1966@gmail.com
Chelysheva E.Yu. – candidate of medical sciences, senior researcher of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: denve@bk.ru
Lazareva O.V. – candidate of medical sciences, researcher of the scientific advisory department of chemotherapy of mieloproliferative diseases, e-mail: stakhino@gmail.com
Ivanova T.V. – head of medical admission unit
Shukhov O.A. – postgraduate student of the scientific advisory department of chemotherapy of mieloproliferative diseases, e-mail: shuhov@list.ru
Bykova A.V. – postgraduate student of the scientific advisory department for chemotherapy myeloproliferative disorders, e-mail: ivlutaya@mail.ru
Abdullaev A.O. – senior researcher in laboratory of molecular genetics, e-mail: adham_abdullaev@mail.ru
Vinogradova O.Yu. – doctor of medical sciences, chief researcher, е-mail: olgavinz.ru
